Clinical Characteristics and Outcomes Among Travelers With Severe Dengue: A GeoSentinel Analysis
This article has been corrected.
VIEW CORRECTIONThis article has been corrected.
VIEW CORRECTIONSubmit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
Visual Abstract. Clinical Characteristics and Outcomes Among Travelers With Severe Dengue
In this retrospective review of travel-associated dengue reported to GeoSentinel, complicated dengue occurred in 95 of 5958 (2%) patients. The most common laboratory findings and signs were thrombocytopenia, elevated aminotransferase, bleeding, and plasma leakage. Clinicians should monitor patients with dengue for warning signs that may indicate progression to severe disease.
Abstract
Background:
Dengue virus is a flavivirus transmitted by Aedes mosquitoes and is an important cause of illness worldwide. Data on the severity of travel-associated dengue illness are limited.
Objective:
To describe the epidemiology, clinical characteristics, and outcomes among international travelers with severe dengue or dengue with warning signs as defined by the 2009 World Health Organization classification (that is, complicated dengue).
Design:
Retrospective chart review and analysis of travelers with complicated dengue reported to GeoSentinel from January 2007 through July 2022.
Setting:
20 of 71 international GeoSentinel sites.
Patients:
Returning travelers with complicated dengue.
Measurements:
Routinely collected surveillance data plus chart review with abstraction of clinical information using predefined grading criteria to characterize the manifestations of complicated dengue.
Results:
Of 5958 patients with dengue, 95 (2%) had complicated dengue. Eighty-six (91%) patients had a supplemental questionnaire completed. Eighty-five of 86 (99%) patients had warning signs, and 27 (31%) were classified as severe. Median age was 34 years (range, 8 to 91 years); 48 (56%) were female. Patients acquired dengue most frequently in the Caribbean (n = 27 [31%]) and Southeast Asia (n = 20 [23%]). Frequent reasons for travel were tourism (45%) and visiting friends and relatives (30%). Twenty-one of 84 (25%) patients had comorbidities. Seventy-eight (91%) patients were hospitalized. One patient died of nondengue-related illnesses. Common laboratory findings and signs were thrombocytopenia (78%), elevated aminotransferase (62%), bleeding (52%), and plasma leakage (20%). Among severe cases, ophthalmologic pathology (n = 3), severe liver disease (n = 3), myocarditis (n = 2), and neurologic symptoms (n = 2) were reported. Of 44 patients with serologic data, 32 confirmed cases were classified as primary dengue (IgM+/IgG−) and 12 as secondary (IgM−/IgG+) dengue.
Limitations:
Data for some variables could not be retrieved by chart review for some patients. The generalizability of our observations may be limited.
Conclusion:
Complicated dengue is relatively rare in travelers. Clinicians should monitor patients with dengue closely for warning signs that may indicate progression to severe disease. Risk factors for developing complications of dengue in travelers need further prospective study.
Primary Funding Source:
Centers for Disease Control and Prevention, International Society of Travel Medicine, Public Health Agency of Canada, and GeoSentinel Foundation.
Get full access to this article
View all available purchase options and get full access to this article.
Supplemental Material
References
1.
Stanaway JD, Shepard DS, Undurraga EA, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:712-723. [PMID: 26874619] doi: 10.1016/S1473-3099(16)00026-8
2.
Zeng Z, Zhan J, Chen L, et al. Global, regional, and national dengue burden from 1990 to 2017: a systematic analysis based on the global burden of disease study 2017. EClinicalMedicine. 2021;32:100712. [PMID: 33681736] doi: 10.1016/j.eclinm.2020.100712
3.
World Health Organization, Special Programme for Research and Training in Tropical Diseases. Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, Special Programme for Research and Training in Tropical Diseases; 2009. Accessed at https://www.who.int/publications/i/item/9789241547871 on 31 January 2023.
4.
Horstick O, Jaenisch T, Martinez E, et al. Comparing the usefulness of the 1997 and 2009 WHO dengue case classification: a systematic literature review. Am J Trop Med Hyg. 2014;91:621-634. [PMID: 24957540] doi: 10.4269/ajtmh.13-0676
5.
Srikiatkhachorn A, Rothman AL, Gibbons RV, et al. Dengue—how best to classify it. Clin Infect Dis. 2011;53:563-567. [PMID: 21832264] doi: 10.1093/cid/cir451
6.
Camprubí-Ferrer D, Cobuccio L, van den Broucke S, et al. Causes of fever in returning travelers: a European multicenter prospective cohort study. J Travel Med. 2022;29(2):taac002. [PMID: 35040473] doi: 10.1093/jtm/taac002
7.
Schwartz E, Weld LH, Wilder-Smith A, et al; GeoSentinel Surveillance Network. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerg Infect Dis. 2008;14:1081-1088. [PMID: 18598629] doi: 10.3201/eid1407.071412
8.
Ratnam I, Leder K, Black J, et al. Dengue fever and international travel. J Travel Med. 2013;20:384-393. [PMID: 24165383] doi: 10.1111/jtm.12052
9.
Halstead S, Wilder-Smith A. Severe dengue in travellers: pathogenesis, risk and clinical management. J Travel Med. 2019;26(7). [PMID: 31423536] doi: 10.1093/jtm/taz062
10.
Tavakolipoor P, Schmidt-Chanasit J, Burchard GD, et al. Clinical features and laboratory findings of dengue fever in German travellers: a single-centre, retrospective analysis. Travel Med Infect Dis. 2016;14:39-44. [PMID: 26876059] doi: 10.1016/j.tmaid.2016.01.007
11.
Hoffmeister B, Suttorp N, Zoller T. The revised dengue fever classification in German travelers: clinical manifestations and indicators for severe disease. Infection. 2015;43:21-28. [PMID: 25421705] doi: 10.1007/s15010-014-0688-z
12.
Trojánek M, Maixner J, Sojková N, et al. Dengue fever in Czech travellers: a 10-year retrospective study in a tertiary care centre. Travel Med Infect Dis. 2016;14:32-38. [PMID: 26159629] doi: 10.1016/j.tmaid.2015.06.005
13.
Tai AY, McGuinness SL, Robosa R, et al. Management of dengue in Australian travellers: a retrospective multicentre analysis. Med J Aust. 2017;206:295-300. [PMID: 28403751] doi: 10.5694/mja16.01056
14.
Muller DA, Depelsenaire AC, Young PR. Clinical and laboratory diagnosis of dengue virus infection. J Infect Dis. 2017;215:S89-S95. [PMID: 28403441] doi: 10.1093/infdis/jiw649
15.
Tomashek KM, Wills B, See Lum LC, et al. Development of standard clinical endpoints for use in dengue interventional trials. PLoS Negl Trop Dis. 2018;12:e0006497. [PMID: 30286085] doi: 10.1371/journal.pntd.0006497
16.
Heinemann M, Bigdon E, Veletzky L, et al. Case report: acute vision loss in a young returning traveler with dengue fever. Am J Trop Med Hyg. 2020;103:2026-2028. [PMID: 32901600] doi: 10.4269/ajtmh.20-0562
17.
Wieten RW, Vlietstra W, Goorhuis A, et al. Dengue in travellers: applicability of the 1975-1997 and the 2009 WHO classification system of dengue fever. Trop Med Int Health. 2012;17:1023-1030. [PMID: 22686428] doi: 10.1111/j.1365-3156.2012.03020.x
18.
Htun NS, Odermatt P, Eze IC, et al. Is diabetes a risk factor for a severe clinical presentation of dengue? Review and meta-analysis. PLoS Negl Trop Dis. 2015;9:e0003741. [PMID: 25909658] doi: 10.1371/journal.pntd.0003741
19.
Zhang H, Zhou YP, Peng HJ, et al. Predictive symptoms and signs of severe dengue disease for patients with dengue fever: a meta-analysis. Biomed Res Int. 2014;2014:359308. [PMID: 25097856] doi: 10.1155/2014/359308
20.
Lien CE, Chou YJ, Shen YJ, et al. A population-based cohort study on chronic comorbidity risk factors for adverse dengue outcomes. Am J Trop Med Hyg. 2021;105:1544-1551. [PMID: 34583328] doi: 10.4269/ajtmh.21-0716
21.
Fonseca-Portilla R, Martínez-Gil M, Morgenstern-Kaplan D. Risk factors for hospitalization and mortality due to dengue fever in a Mexican population: a retrospective cohort study. Int J Infect Dis. 2021;110:332-336. [PMID: 34332086] doi: 10.1016/j.ijid.2021.07.062
22.
Sangkaew S, Ming D, Boonyasiri A, et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21:1014-1026. [PMID: 33640077] doi: 10.1016/S1473-3099(20)30601-0
23.
Ng WY, Atan R, Mohd Yunos N, et al. A double whammy: the association between comorbidities and severe dengue among adult patients—a matched case-control study. PLoS One. 2022;17:e0273071. [PMID: 36126060] doi: 10.1371/journal.pone.0273071
24.
Werneck GL, Macias AE, Mascarenas C, et al. Comorbidities increase in-hospital mortality in dengue patients in Brazil. Mem Inst Oswaldo Cruz. 2018;113:e180082. [PMID: 30043823] doi: 10.1590/0074-02760180082
25.
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5.0 Accessed at https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm on 31 January 2023.
26.
Ng AW, Teoh SC. Dengue eye disease. Surv Ophthalmol. 2015;60:106-114. [PMID: 25223497] doi: 10.1016/j.survophthal.2014.07.003
27.
Carod-Artal FJ, Wichmann O, Farrar J, et al. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12:906-919. [PMID: 23948177] doi: 10.1016/S1474-4422(13)70150-9
28.
Yacoub S, Wertheim H, Simmons CP, et al. Cardiovascular manifestations of the emerging dengue pandemic. Nat Rev Cardiol. 2014;11:335-345. [PMID: 24710495] doi: 10.1038/nrcardio.2014.40
29.
Rahim A, Hameed A, Ishaq U, et al. Cardiovascular sequelae of dengue fever: a systematic review. Expert Rev Cardiovasc Ther. 2022;20:465-479. [PMID: 35612830] doi: 10.1080/14779072.2022.2082945
30.
Fongwen N, Delrieu I, Ham LH, et al. Implementation strategies for the first licensed dengue vaccine: a meeting report. Vaccine. 2021;39:4759-4765. [PMID: 34253416] doi: 10.1016/j.vaccine.2021.06.083
31.
Biswal S, Reynales H, Saez-Llorens X, et al; TIDES Study Group. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med. 2019;381:2009-2019. [PMID: 31693803] doi: 10.1056/NEJMoa1903869
32.
Rivera L, Biswal S, Sáez-Llorens X, et al. Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis. 2022;75:107-117. [PMID: 34606595] doi: 10.1093/cid/ciab864
33.
Schnabel I, Schneitler S, Schüttoff T, et al. Diagnostic specificity of two dengue virus IgG ELISAs after yellow fever and Japanese encephalitis virus vaccination. Trop Med Infect Dis. 2022;8(1). [PMID: 36668914] doi: 10.3390/tropicalmed8010007
34.
Katzelnick LC, Zambrana JV, Elizondo D, et al. Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term. Sci Transl Med. 2021;13:eabg9478. [PMID: 34613812] doi: 10.1126/scitranslmed.abg9478
Information & Authors
Information
Published In
Annals of Internal Medicine
Volume 176 • Number 7 • July 2023
Pages: 940 - 948
History
Published online: 20 June 2023
Published in issue: July 2023
Keywords
Copyright
© 2023 American College of Physicians.
Authors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
Download article citation data for:
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue: A GeoSentinel Analysis. Ann Intern Med.2023;176:940-948. [Epub 20 June 2023]. doi:10.7326/M23-0721
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue: A GeoSentinel Analysis. Ann Intern Med.2023;176:940-948. [Epub 20 June 2023]. doi:10.7326/M23-0721
View More
Get Access
Login Options:
Purchase
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.
Create your Free Account
You will be redirected to acponline.org to create an account that will provide access to Annals.
Comments
0 Comments